RVMD
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes
Article Summary
HOLD- Revolution Medicines Inc. (NASDAQ: REVA) priced concurrent public offerings of 10,563,381 shares of common stock at $142.00 per share and $500.0 million aggregate principal amount of 0.50% convertible senior notes due 2033 for aggregate gross proceeds of approximately $1.5 billion.
- The late-stage clinical oncology company is developing targeted therapies for patients with RAS-addicted cancers and granted underwriters of the common stock offering a 30-day option to purchase up to 1,584,506 shares, with completion of the offering not contingent on completion of note offering.
- The notes will mature on May 1, 2033 unless earlier repurchased, redeemed or converted, with the initial conversion rate of 5.0302 shares per $1,000 of notes representing an initial conversion price of about $198.80 per share, representing a premium of approximately 40.0% over the public offering price per share in common stock.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | -100.0% | 25% | 0.0 ptsDeclining (-100.0%) - NOT a growth stock |
| EPS Growth Next 5Y ? | 14.8% | 25% | 35.0 ptsBelow Screener (14.8%) - Modest outlook |
| Target Price Upside ? | 6.2% | 20% | 35.0 ptsBelow Screener (6.2%) - Target: $156.10 vs Current: $147.01 |
| Gross Margin % ? | — | 15% | 40.0 ptsNo Gross Margin Data |
| Drawdown from 52-Wk High ? | 7.5% | 15% | 20.0 ptsBarely a Dip (7.5%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About RVMD
- Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
- The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.
- Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C).
- Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.